PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTigecycline
Tygacil(tigecycline)
Tigecycline, Tygacil (tigecycline) is a small molecule pharmaceutical. Tigecycline was first approved as Tygacil on 2005-06-15. It is used to treat bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bacteroides infections amongst others in the USA. It has been approved in Europe to treat bacterial infections, bacterial skin diseases, infectious skin diseases, intraabdominal infections, and soft tissue infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Tigecycline, Tygacil (discontinued: Tigecycline)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tigecycline
Tradename
Company
Number
Date
Products
TIGECYCLINEAmneal PharmaceuticalsN-211158 RX2018-08-02
1 products
TIGECYCLINEFresenius KabiN-205645 RX2016-12-01
1 products, RLD, RS
TYGACILCV SciencesN-021821 RX2005-06-15
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
tigecyclineANDA2025-06-30
tygacilNew Drug Application2025-04-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
intraabdominal infections—D059413—
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
clostridium infectionsEFO_1000874D003015A05.2
streptococcal infectionsEFO_1001476D013290—
bacterial pneumoniaEFO_1001272D018410J15.9
staphylococcal infections—D013203A49.01
bacteremiaEFO_0003033D016470R78.81
klebsiella infectionsEFO_1001353D007710—
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Tigecycline, Tigecycline, Amneal
98553352033-04-07DP
Tigecycline, Tygacil, Pf Prism Cv
83729952030-10-08DP
78798282029-02-05DP
89752422028-10-24DP
92543282026-03-13DP
96940782026-03-13DP
105889752026-03-13DP
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA12: Tigecycline
HCPCS
Code
Description
J3243
Injection, tigecycline, 1 mg
J3244
Injection, tigecycline (accord) not therapeutically equivalent to j3243, 1 mg
Clinical
Clinical Trials
84 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544———1258
Communicable diseasesD003141————1247
Intraabdominal infectionsD059413————1247
PneumoniaD011014EFO_0003106J18—11114
Healthcare-associated pneumoniaD000077299———1—1—2
ObesityD009765EFO_0001073E66.9———1—1
Ventilator-associated pneumoniaD053717EFO_1001865J95.851———1—1
Urinary tract infectionsD014552EFO_0003103N39.0———1—1
BacteremiaD016470EFO_0003033R78.81———1—1
PyelonephritisD011704EFO_1001141N10-N16———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial pneumoniaD018410EFO_1001272J15.9—11—13
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Infectious skin diseasesD012874——————22
Skin diseasesD012871—L00-L99————22
Soft tissue infectionsD018461——————11
DiarrheaD003967—R19.7————11
Clostridium infectionsD003015EFO_1000874A05.2————11
Clostridioides difficileD016360NCBITaxon_1496—————11
Community-acquired infectionsD017714——————11
Staphylococcus aureusD013211NCBITaxon_1280—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTigecycline
INNtigecycline
Description
Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.
Classification
Small molecule
Drug classantibiotics (tetracycline derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Identifiers
PDB—
CAS-ID220620-09-7
RxCUI—
ChEMBL IDCHEMBL376140
ChEBI ID149836
PubChem CID5282044
DrugBankDB00560
UNII ID70JE2N95KR (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Tygacil – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 19,857 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tigecycline, Tygacil
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,511 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use